<DOC>
	<DOCNO>NCT00700115</DOCNO>
	<brief_summary>This study examine effectiveness safety raltegravir ( isentress ) use together lopinavir/ritonavir ( kaletra ) treatment HIV-infection . Isentress recently , Food Drug Administration ( FDA ) approve , HIV medication strong effect HIV virus . Isentress show study safe well tolerate HIV patient . Combining drug kaletra might enable u construct HIV regimen include toxic drug nucleoside reverse transcriptase inhibitor class . Eligible volunteer undergo follow part study procedure : 1 . Sign study consent form HIPAA Authorization Form . 2 . Two-third subject , intervention group ( select random chance ) HIV drug treatment change kaletra + isentress . 3 . The one-third continue usual HIV medication ( control group ) . 4 . Make 9 study relate visit Ponce clinic 48 week study period . During visit , medical information collect , blood test perform . 5 . Perform Dexa-scan two separate occasion Emory University Hospital Radiology . Information collect used ass effectiveness treatment keep HIV virus suppress , well two drug together tolerate HIV-infected patient , blood level two drug give together .</brief_summary>
	<brief_title>Kaletra-isentress Treatment Evaluation</brief_title>
	<detailed_description>RATIONALE : Virologic failure adverse effect associate current highly active antiretroviral therapy ( HAART ) warrant continue search novel combination therapeutic option . Raltegravir 's ( RAL ) recently show potent antiretroviral ( ARV ) agent favorable safety profile . If future report continue show positive data first-in-class integrase inhibitor , may paradigm shift currently recommend first line HAART regimens include integrase inhibitor . Combining RAL drug high genetic barrier resistance , lopinavir/ritonavir ( LPV/r ) may offer number advantage . Both agent potent produce durable virologic suppression . Because combination reverse transcriptase inhibitor ( RTI ) class sparing , tolerability might superior . In addition , RAL metabolize cytochrome P-450 enzyme , therefore , compatible pharmacokinetic profile expect combination . Pairing LPV/r RAL early ARV regimen propose application may provide HAART regimen highly efficacious durable , less resistance adverse drug event . DESIGN : This single center , open label , randomize , control , study design assess tolerability , pharmacokinetic compatibility , durability virologic suppression RTI spar combination therapy LPV/r + RAL . HIV-infected subject virologically suppress ( HIV-RNA PCR &lt; 50 copies/ml ) current HAART regimen randomize 2:1 fashion switch regimen consist LPV/r + RAL , intervention arm A ( n=40 ) , continue pre-study HAART regimen , control arm B ( n=20 ) . The primary endpoint proportion subject sustain virologic suppression ( HIV-1 RNA PCR &lt; 50 copies/ml ) week 48 . The immunoreconstitution , toxicity profile , pharmacokinetic profile RAL LPV/r novel combination therapy evaluate . DURATION : 48 week enrollment last participant . Enrollment expect take 10 month . SAMPLE SIZE : 60 subject . POPULATION : HIV-infected individual ( male female ) , Age &gt; 18 year , virologically suppress ( HIV-RNA PCR &lt; 50 copies/ml ) current HAART regimen &gt; 6 month . REGIMEN : For Arm A= LPV/r 400/100 mg ( 2 tablet ) twice daily + RAL 400 mg ( 1 tablet ) twice daily take mouth . For Arm B=Pre-study HAART regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1infected individual receive HAART regimen ( PIbased regimen , must 1st PIcontaining HAART ) . They must tolerate current HAART regimen &gt; 6months . Plasma HIV1 viral load &lt; 50 copies/ml study entry . Men woman age &gt; 18 year ( sex define sex birth ) . Laboratory value obtain within 30 day prior study entry : Hemoglobin &gt; 9.4 g/dl Creatinine &lt; 2 mg/dl AST ( SGOT ) &lt; 2 x ULN ALT ( SGPT ) &lt; 2 x ULN Ability willingness subject legal guardian/representative give write informed consent . No CD4 Tcell count requirement Subjects history previous intolerance virological failure LPV/r Concomitant drug ( include alternative therapy ) may affect PI RAL plasma concentration ( inducer inhibitor CYP 3A4 UDPglucuronosyltransferase isoenzymes ) . A known history noncompliance medication know history noncompliance schedule physician clinic visit . Investigational ARV drug . Pregnancy/Breast feeding . HBVcoinfected patient receive nucleoside analogue HIV HBV suppression . Active drug alcohol use dependence , Investigator 's opinion , may interfere adherence study requirement endanger subject 's health study . Serious illness require systemic treatment and/or hospitalization within 30 day prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>HAART</keyword>
	<keyword>lopinavir/ritonavir</keyword>
	<keyword>raltegravir</keyword>
	<keyword>HIV/AIDS patient HAART</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>